| CAS ID: | 1216941-48-8 |
| Molecular Formula: | C40H43N7O7S |
| Molecular Weight: | 765.9 g/mol |
| Monoisotopic Mass: | 765.2945 g/mol |
| Class: | Small Molecule |
| Natural Product: | No |
| Other Names: | ABT-450 | PARITAPREVIR |
| Analysis: | Drug repositioning mechanism analysis |
| InChI: | InChI=1S/C40H43N7O7S/c1-24-21-42-33(22-41-24)35(48)43-32-16-6-4-2-3-5-11-25-20-40(25,39(51)46-55(52,53)27-17-18-27)45-36(49)34-19-26(23-47(34)38(32)50)54-37-30-14-8-7-12-28(30)29-13-9-10-15-31(29)44-37/h5,7-15,21-22,25-27,32,34H,2-4,6,16-20,23H2,1H3,(H,43,48)(H,45,49)(H,46,51)/b11-5-/t25-,26-,32+,34+,40-/m1/s1 | See All |
| InChI Key: | UAUIUKWPKRJZJV-QPLHLKROSA-N | |
| Smiles: | Cc1cnc(cn1)C(=O)N[C@H]2CCCCC\C=C/[C@@H]3C[C@]3(NC(=O)[C@@H]4C[C@H](CN4C2=O)Oc5nc6ccccc6c7ccccc57)C(=O)NS(=O)(=O)C8CC8 | See All |
| Molfile: | Download |
Trial Record 1
| ClinicalTrial ID | NCT02442284 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | May 13, 2015 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 2
| ClinicalTrial ID | NCT02806362 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Withdrawn |
| First Received | June 20, 2016 | Last Verified | December 5, 2016 |
| Sponsor | AbbVie | ||
Trial Record 3
| ClinicalTrial ID | NCT02265237 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 15, 2014 | Last Verified | August 31, 2017 |
| Sponsor | AbbVie | ||
Trial Record 4
| ClinicalTrial ID | NCT02219477 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | July 11, 2017 |
| Sponsor | AbbVie | ||
Trial Record 5
| ClinicalTrial ID | NCT02207088 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 1, 2014 | Last Verified | November 9, 2017 |
| Sponsor | AbbVie | ||
Trial Record 6
| ClinicalTrial ID | NCT01995071 | Disease | Liver fibrosis |
| Phase | Phase 2 | Status | Completed |
| First Received | November 26, 2013 | Last Verified | October 16, 2017 |
| Sponsor | AbbVie | ||
Trial Record 7
| ClinicalTrial ID | NCT02517528 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 7, 2015 | Last Verified | October 8, 2018 |
| Sponsor | AbbVie | ||
Trial Record 8
| ClinicalTrial ID | NCT01704755 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | October 11, 2012 | Last Verified | October 19, 2015 |
| Sponsor | AbbVie (prior sponsor, Abbott) | ||
Trial Record 9
| ClinicalTrial ID | NCT02219503 | Disease | Liver fibrosis |
| Phase | Phase 3 | Status | Completed |
| First Received | August 19, 2014 | Last Verified | June 29, 2016 |
| Sponsor | AbbVie | ||
Trial Record 10
| ClinicalTrial ID | NCT01939197 | Disease | Liver fibrosis |
| Phase | Phase 2,Phase 3 | Status | Completed |
| First Received | September 11, 2013 | Last Verified | November 17, 2017 |
| Sponsor | AbbVie | ||
Trial Record 11
| ClinicalTrial ID | NCT03053180 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | February 15, 2017 | Last Verified | March 14, 2019 |
| Sponsor | AbbVie | ||
Trial Record 12
| ClinicalTrial ID | NCT02640547 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 29, 2015 | Last Verified | October 17, 2018 |
| Sponsor | AbbVie | ||
Trial Record 13
| ClinicalTrial ID | NCT02636608 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | December 22, 2015 | Last Verified | May 30, 2018 |
| Sponsor | AbbVie | ||
Trial Record 14
| ClinicalTrial ID | NCT02615145 | Disease | Liver fibrosis |
| Phase | Status | Completed | |
| First Received | November 26, 2015 | Last Verified | April 12, 2018 |
| Sponsor | AbbVie | ||
| PubChem: | 45110509 |
| ChEMBL: | CHEMBL3391662 |